Allogene Therapeutics, Inc. ALLO
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is an oncology drug developer. Its lead program, cemacabtagene ansegedleucel (cema-cel, ALLO-501A), is in Phase 2 for 1L consolidation in newly diagnosed large B-cell lymphoma (MRD+ after first-line therapy). Its next catalyst on record is ALLO-329: initial data (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ALLO-329 — initial data (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| cema-cel | 1L LBCL consolidation (ALPHA3 pivotal) | cell therapy | Phase 2 |
| ALLO-316 | renal cell carcinoma (TRAVERSE) | cell therapy | Phase 1 |
| ALLO-329 | autoimmune disease (RESOLUTION) | cell therapy | Phase 1 |
Recent results and decisions
- Apr 13, 2026positive Interim futility analysis (24 pts): MRD negativity 58.3% (7/12) with cema-cel vs 16.7% (2/12) observation; no CRS, ICANS or GvHD; primary EFS endpoint remains blinded.
At the protocol-defined data cutoff date, 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity compared to 16.7% (2/12) in the observation arm.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.